Actuate Therapeutics, Inc. Common stock (ACTU) News
Follow Actuate Therapeutics, Inc. Common stock (ACTU) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Actuate Therapeutics Raises $9.96 Million in Stock-and-Warrant Offering
Actuate Therapeutics closed a public offering on October 28, 2026, raising approximately $9.96 million in net proceeds from common stock and warrant sales.
EQUITY | Oct 28, 2026, 09:23 PM UTC
M
Actuate Therapeutics Prices $11 Million Offering of Shares and Warrants
Actuate Therapeutics priced a public offering of shares and warrants totaling $11 million.
EQUITY | Oct 27, 2026, 12:13 PM UTC
H
Why Penguin Solutions Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Shares of Penguin Solutions, Inc. (NYSE: PENG ) rose sharply in pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued FY27 EPS guidance above estimates. The compan
LIVE | Oct 07, 2026, 08:38 AM UTC
L
ACTU: Oral elraglusib shows strong survival benefits and synergy, with pivotal trials set to begin soon
Oral elraglusib is advancing to clinical trials, aiming to improve survival in metastatic pancreatic and other cancers, with strong efficacy and synergy data supporting its use in combination regimens. Pediatric trials a
NEWS | Sep 14, 2026, 11:14 PM UTC
L
ACTU: Oral elraglusib advances to trials, targeting improved survival and synergy in tough cancers
Oral elraglusib is advancing to clinical trials after demonstrating significant survival benefits and synergy with RAS inhibitors in hard-to-treat cancers. The oral pivot aims to improve patient exposure and convenience,
NEWS | Sep 14, 2026, 11:08 PM UTC
L
ACTU: Oral elraglusib advances with strong efficacy, synergy in combinations, and pivotal pediatric trials
Elraglusib, a GSK-3β inhibitor, demonstrated significant survival benefits in metastatic pancreatic cancer and is advancing to an oral formulation to improve patient outcomes and enable daily dosing. The strategy include
NEWS | Sep 14, 2026, 10:33 PM UTC
L
Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference
CHICAGO and FORT WORTH, Texas, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. NASDAQ:ACTU (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the t
EQUITY | Sep 09, 2026, 09:02 PM UTC
L
ACTU - Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference
ACTU - Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference
EQUITY | Sep 09, 2026, 09:00 PM UTC
L
Actuate announces preclinical synergy for elraglusib with RAS inhibitors
Actuate Therapeutics said it announced new preclinical data showing synergistic activity of elraglusib with RAS inhibitors zoldonrasib and daraxonrasib.
EQUITY | Sep 09, 2026, 11:01 AM UTC
L
Actuate announces preclinical combo synergy for elraglusib
Actuate said preclinical data show synergistic activity of elraglusib with RAS inhibitors zoldonrasib and daraxonrasib.
EQUITY | Sep 09, 2026, 11:01 AM UTC